Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.
Approval Alert | Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
